Table 3.
Multivariate analysis of locoregional recurrence in patients with breast cancer who received neoadjuvant chemotherapy followed by total mastectomy.
| Locoregional recurrence |
||||
|---|---|---|---|---|
| HR | (95% CI) | p value | ||
| PMRT | No | Ref | <0.0001 | |
| Yes | 0.51 | (0.41–0.58) | ||
| Age | 20–49 | Ref | 0.28 | |
| 50+ | 0.93 | (0.84–1.06) | ||
| Diagnosis year | 2007–2010 | Ref | 0.43 | |
| 2011–2015 | 1.05 | (0.92–1.18) | ||
| CCI scores | 0 | Ref | 0.54 | |
| 1 | 1.03 | (0.91–1.26) | ||
| 2+ | 1.16 | (0.90–1.50) | ||
| Differentiation | Poor | Ref | 0.0081 | |
| Moderate | 0.88 | (0.75–0.94) | ||
| Well | 0.64 | (0.46–0.88) | ||
| AJCC clinical stages | I | Ref | <0.0001 | |
| II | 1.25 | (0.76–1.97) | ||
| III | 1.52 | (1.01–2.34) | ||
| IV | 1.85 | (1.17–2.89) | ||
| ypT | ypT0 | Ref | <0.0001 | |
| ypT1 | 1.61 | (1.15–2.29) | ||
| ypT2 | 1.81 | (1.29–2.51) | ||
| ypT3–4 | 2.48 | (1.70–3.24) | ||
| ypN | ypN0 | Ref | 0.0013 | |
| ypN1 | 1.40 | (1.16–1.72) | ||
| ypN2–3 | 2.22 | (1.84–1.93) | ||
| NACT regimen | Anthracycline | Ref | 0.19 | |
| Taxanes | 1.03 | (0.96–1.09) | ||
| Both | 1.10 | (0.94–1.30) | ||
| Neither | 1.12 | (0.98–1.65) | ||
| Nodal surgery | SLNB | Ref | 0.44 | |
| ALND | 1.29 | (0.93–1.80) | ||
| ER/PR positive | Negative | Ref | 0.22 | |
| Positive | 1.03 | (0.93–1.27) | ||
| HER2 positive | Negative | Ref | <0.0001 | |
| Positive | 1.56 | (1.34–1.70) | ||
| Hospital level | Academic | Ref | 0.59 | |
| Others | 1.02 | (0.90–1.16) | ||
HR, hazard ratio; CI, confidence interval; PMRT, postmastectomy radiation therapy; T, tumor; N, nodal; NACT, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; CCI, Charlson comorbidity index; AJCC, American Joint Committee on Cancer; ypT, postchemotherapy pathologic tumor stages; ypN, postchemotherapy pathologic nodal stages.